Tareck Ayad

Tareck Ayad

Auto-generated profile, based on publicly available information

Tareck Ayad

Department of Otolaryngology—Head and Neck Surgery Centre Hospitalier de L'université de Montréal (CHUM) Montreal Canada

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Otolaryngology - Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
FGFanny Gabrysz-Forget
Fanny Gabrysz-Forget
PTPaul Tabet
Paul Tabet
ARAkram Rahal
Akram Rahal
EBEric Bissada
Eric Bissada
ACApostolos Christopoulos
Apostolos Christopoulos
TATareck Ayad
Tareck Ayad
Objective: The present review focuses on comparative studies of reconstruction with free flaps (FF) versus pedicled flaps (PF) after oncologic resection. Method: A systematic review was developed in compliance with PRISMA guidelines and performed using the Pubmed, Medline, EMBASE, Amed and Biosis databases. Results: A total of 30 articles were included. FF are associated with a longer operative time, a higher cost and a higher incidence of postoperative revisions compared to PF. FF are associated with a longer stay at the intensive care unit than the supraclavicular artery island flap (SCAIF) and with a more extended hospital stay compared to the submental island flap (SMIF). FF are associated with fewer infections and necrosis compared to the pectoralis major myocutaneous flap (PMMF). Conclusion: The comparison of both type of flaps is limited by the inherent design of the studies included. In sum, FF seem superior to the PMMF for several outcomes. SMIF and SCAIF compare favorably to FF for some specific indications achieving similar outcomes at a lower cost.

1 September 2014 in Head & Neck
Verified
Journal Article
Closed access
PDF file
TATareck Ayad
Tareck Ayad
LXLiyue Xie
Liyue Xie

1 September 2020 in Oral Oncology
Verified
Journal Article
Closed access
CECarlos M Chiesa Estomba
Carlos M Chiesa Estomba
JLJérome R. Lechien
Jérome R. Lechien
CCChristian Calvo-Henríquez
Christian Calvo-Henríquez
NFNicolas Fakhry
Nicolas Fakhry
PKPetros D. Karkos
Petros D. Karkos
TATareck Ayad
Tareck Ayad

26 October 2017 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
JBJosiane Bolduc-Bégin
Josiane Bolduc-Bégin
FPFrançois Prince
François Prince
ACApostolos Christopoulos
Apostolos Christopoulos
TATareck Ayad
Tareck Ayad

1 October 2020 in Oral Oncology
Verified
Journal Article
Closed access
Jerome R. LechienJerome R. Lechien
Jerome R. Lechien
NFNicolas Fakhry
Nicolas Fakhry
Sven SaussezSven Saussez
Sven Saussez
CCCarlos-Miguel Chiesa-Estomba
Carlos-Miguel Chiesa-Estomba
YCYounes Chekkoury-Idrissi
Younes Chekkoury-Idrissi
SHStéphane Hans
Stéphane Hans

14 January 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HBHouda Bahig
Houda Bahig
FAFrancine Aubin
Francine Aubin
John StaggJohn Stagg
John Stagg
OGOlguta Gologan
Olguta Gologan
OBOlivier Ballivy
Olivier Ballivy
PWPhilip Wong
Philip Wong
The efficacy of immunotherapy targeting the PD-1/PD-L1 pathway has previously been demonstrated in metastatic head and neck squamous cell carcinoma (HNSCC). Stereotactic Body Radiotherapy (SBRT) aims at ablating metastatic lesions and may play a synergistic role with immunotherapy. The purpose of this study is to assess the safety and efficacy of triple treatment combination (TTC) consisting of the administration of durvalumab and tremelimumab in combination with SBRT in metastatic HNSCC. This is a phase I/II single arm study that will include 35 patients with 2–10 extracranial metastatic lesions. Patients will receive durvalumab (1500 mg IV every 4 weeks (Q4W)) and tremelimumab (75 mg IV Q4W for a total of 4 doses) until progression, unacceptable toxicity or patient withdrawal. SBRT to 2–5 metastases will be administered between cycles 2 and 3 of immunotherapy. The safety of the treatment combination will be evaluated through assessment of TTC-related toxicities, defined as grade 3–5 toxicities based on Common Terminology Criteria for Adverse Events (v 4.03), occurring within 6 weeks from SBRT start, and that are definitely, probably or possibly related to the combination of all treatments. We hypothesize that dual targeting of PD-L1 and CTLA-4 pathways combined with SBRT will lead to < 35% grade 3–5 acute toxicities related to TTC. Progression free survival (PFS) will be the primary endpoint of the phase II portion of this study and will be assessed with radiological exams every 8 weeks using the RECIST version 1.1 criteria. The combination of synergistic dual checkpoints inhibition along with ablative radiation may significantly potentiate the local and systemic disease control. This study constitutes the first clinical trial combining effects of SBRT with dual checkpoint blockade with durvalumab and tremelimumab in the treatment of metastatic HNSCC. If positive, this study would lead to a phase III trial testing this treatment combination against standard of care in metastatic HNSCC. NCT03283605 . Registration date: September 14, 2017; version 1.